SUMOylation involved in malignant progression of multiple tumors and SENP5 may improve the chemotherapy sensitivity of hypoxic tumors
Our findings indicate that inhibition of the SUMOylation pathway is a promising therapeutic strategy. The broader implication of our study is that the precision and safety of this approach are contingent upon targeting specific components such as SENP5, which offers a superior therapeutic window by avoiding the adverse effects associated with global SUMOylation inhibition.
Authors
- Wenhan Wu (ORCID: https://orcid.org/0000-0002-4284-9016)
- Bing Han (ORCID: https://orcid.org/0000-0003-3447-0513)
- Xiaozhi Liu (ORCID: https://orcid.org/0000-0002-5640-4472)
- Min Liu (ORCID: https://orcid.org/0000-0002-4641-7712)
- Chunyan Zhang
- Yuxiang Wang (ORCID: https://orcid.org/0000-0002-1261-3985)
- Yafei Liu (ORCID: https://orcid.org/0000-0002-4141-5259)
- Yanxia Li (ORCID: https://orcid.org/0000-0002-1938-4118)
- Zhongmin Jiang
Institutions
- Tianjin University (CN)
- Peking University (CN)
- Fifth Tianjin Central Hospital (CN)
- Peking University First Hospital (CN)
- Qingdao Huanghai University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-11-05
- DOI
- https://doi.org/10.3389/fphar.2025.1648271
- Primary Topic
- Ubiquitin and proteasome pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00